ATE381560T1 - Neue benzazepine und ähnliche heterocyclische derivate,die als orexin rezeptor antagonisten geeignet sind - Google Patents

Neue benzazepine und ähnliche heterocyclische derivate,die als orexin rezeptor antagonisten geeignet sind

Info

Publication number
ATE381560T1
ATE381560T1 AT01988048T AT01988048T ATE381560T1 AT E381560 T1 ATE381560 T1 AT E381560T1 AT 01988048 T AT01988048 T AT 01988048T AT 01988048 T AT01988048 T AT 01988048T AT E381560 T1 ATE381560 T1 AT E381560T1
Authority
AT
Austria
Prior art keywords
receptor antagonists
heterocyclic derivatives
orexin receptor
derivatives suitable
benzazepines
Prior art date
Application number
AT01988048T
Other languages
English (en)
Inventor
Hamed Aissaoui
Martine Clozel
Thomas Weller
Ralf Koberstein
Thierry Sifferlen
Walter Fischli
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Application granted granted Critical
Publication of ATE381560T1 publication Critical patent/ATE381560T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D267/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02Seven-membered rings
    • C07D267/08Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings
    • C07D281/04Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT01988048T 2000-12-27 2001-12-19 Neue benzazepine und ähnliche heterocyclische derivate,die als orexin rezeptor antagonisten geeignet sind ATE381560T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2000/013289 WO2002051232A2 (en) 2000-12-27 2000-12-27 Novel benzazepines and related heterocyclic derivatives

Publications (1)

Publication Number Publication Date
ATE381560T1 true ATE381560T1 (de) 2008-01-15

Family

ID=8164232

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01988048T ATE381560T1 (de) 2000-12-27 2001-12-19 Neue benzazepine und ähnliche heterocyclische derivate,die als orexin rezeptor antagonisten geeignet sind

Country Status (18)

Country Link
US (1) US7192950B2 (de)
EP (1) EP1347967B1 (de)
JP (1) JP4219166B2 (de)
KR (1) KR100849569B1 (de)
CN (1) CN1261430C (de)
AT (1) ATE381560T1 (de)
AU (1) AU2002240855B2 (de)
BR (1) BR0116505A (de)
CA (1) CA2431982C (de)
DE (1) DE60132017T2 (de)
ES (1) ES2296825T3 (de)
HU (1) HUP0301665A3 (de)
IL (2) IL155806A0 (de)
MX (1) MXPA03004779A (de)
NO (1) NO326158B1 (de)
NZ (1) NZ525613A (de)
WO (2) WO2002051232A2 (de)
ZA (1) ZA200303697B (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
IL159105A0 (en) * 2001-06-07 2004-05-12 Neuro3D Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7279578B2 (en) * 2002-10-11 2007-10-09 Actelion Pharmaceuticals Ltd. Sulfonylamino-acetic acid derivatives
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1603450A4 (de) 2003-03-07 2009-07-29 Univ Columbia Verfahren auf basis von typ 1 ryanodin-rezeptor
MXPA05010137A (es) * 2003-03-26 2005-11-16 Actelion Pharmaceuticals Ltd Derivados de tetrahidroisoquinolil acetamida para usarse como antagonistas del receptor de orexina.
US7321065B2 (en) * 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
DE602004011204T2 (de) 2003-04-28 2008-12-24 Actelion Pharmaceuticals Ltd. Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
EP1660454A1 (de) * 2003-07-07 2006-05-31 Vernalis (R&D) Limited Azazyklische verbindungen als inhibitoren von sns (sensory neurone specific)-kanalen
AU2004274309B2 (en) 2003-09-22 2010-04-08 Msd K.K. Novel piperidine derivative
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
PT1751111E (pt) 2004-03-01 2015-04-01 Actelion Pharmaceuticals Ltd Derivados de 1,2,3,4-tetrahidroisoquinolina substituída
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
EP2286840A3 (de) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Behandlung von Fettleibigkeit und von verwandten Krankheiten
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
GB0500300D0 (en) * 2005-01-07 2005-02-16 Ionix Pharmaceuticals Ltd Chemical compositions
US7501395B2 (en) * 2005-04-25 2009-03-10 Eisai R & D Management Co., Ltd. Method of screening for antianxiety drugs
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
CA2609388C (en) 2005-05-30 2013-08-06 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
JPWO2007018248A1 (ja) 2005-08-10 2009-02-19 萬有製薬株式会社 ピリドン化合物
EP2330124B1 (de) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybridpolypeptide mit auswählbaren Eigenschaften
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
EP1921065B1 (de) 2005-08-24 2010-10-20 Banyu Pharmaceutical Co., Ltd. Phenylpyridonderivat
WO2007029847A1 (ja) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. 二環性芳香族置換ピリドン誘導体
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
WO2007048027A2 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
AU2006307046A1 (en) 2005-10-27 2007-05-03 Msd K.K. Novel benzoxathiin derivative
US8158791B2 (en) 2005-11-10 2012-04-17 Msd K.K. Aza-substituted spiro derivatives
US20090082394A1 (en) * 2006-03-15 2009-03-26 Actelion Pharmaceuticals, Ltd. Tetrahydroisoquinoline Derivatives to Enhance Memory Function
MX2008013238A (es) 2006-04-12 2008-10-21 Merck & Co Inc Antagonistas de los canales de calcio de tipo t de piridil amida.
ATE496051T1 (de) * 2006-04-26 2011-02-15 Actelion Pharmaceuticals Ltd Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
CA2657623A1 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
WO2008026149A1 (en) * 2006-08-28 2008-03-06 Actelion Pharmaceuticals Ltd 1,4,5,6, 7,8-hexahydro-i^1s-triaza-azulene derivatives as orexin receptor antagonists
JP5489333B2 (ja) 2006-09-22 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション 脂肪酸合成阻害剤を用いた治療の方法
AU2007301126A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
ATE528306T1 (de) * 2006-11-02 2011-10-15 Piramal Life Sciences Ltd Benzoxazepin-verbindungen, ihre herstellung und verwendung
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
ATE545647T1 (de) 2006-12-22 2012-03-15 Actelion Pharmaceuticals Ltd 5,6,7,8-tetrahydro-imidazoä1,5-aüpyrazinderivat
WO2008108445A1 (ja) 2007-03-07 2008-09-12 Takeda Pharmaceutical Company Limited ベンゾオキサゼピン誘導体およびその用途
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
CN101646668A (zh) * 2007-04-04 2010-02-10 弗·哈夫曼-拉罗切有限公司 作为食欲肽拮抗剂的杂环类
US9096546B2 (en) 2007-05-10 2015-08-04 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
CA2688776A1 (en) 2007-05-18 2008-11-27 Merck & Co., Inc. Oxo bridged diazepan orexin receptor antagonists
WO2008150364A1 (en) 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
JP4881476B2 (ja) 2007-05-23 2012-02-22 メルク・シャープ・エンド・ドーム・コーポレイション ピリジルピペリジン・オレキシン受容体アンタゴニスト
EP2527360B1 (de) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2698666A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
CN101910133A (zh) 2007-10-24 2010-12-08 默沙东公司 杂环苯基酰胺t-型钙通道拮抗剂
KR101579992B1 (ko) 2007-12-28 2015-12-23 액테리온 파마슈티칼 리미티드 삼치환된 3,4-디하이드로-1h-이소퀴놀린 화합물, 상기 화합물의 제조 공정 및 상기 화합물의 용도
US20110015181A1 (en) 2008-03-06 2011-01-20 Makoto Ando Alkylaminopyridine derivative
EP2272841A1 (de) 2008-03-28 2011-01-12 Banyu Pharmaceutical Co., Ltd. Diarylmethylamidderivat mit antagonistischer wirkung auf rezeptor des melaninkonzentrierenden hormons
EP2810951B1 (de) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
AU2009261248A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
EP3241839B1 (de) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
WO2010013595A1 (ja) 2008-07-30 2010-02-04 萬有製薬株式会社 5員-5員又は5員-6員縮環シクロアルキルアミン誘導体
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
CN102459248A (zh) * 2009-05-26 2012-05-16 埃克塞里艾克西斯公司 作为PI3K/mTOR抑制剂的苯并氧杂环庚三烯以及它们使用与制造方法
EP2504316A1 (de) 2009-11-23 2012-10-03 MSD Oss B.V. Heterocylische verbindungen als orexinrezeptorantagonisten
FR2956401B1 (fr) 2010-02-17 2012-02-03 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
BR112013021236B1 (pt) 2011-02-25 2021-05-25 Merck Sharp & Dohme Corp composto derivado de benzimidazol, e, composição
BR112014003704A2 (pt) 2011-09-19 2017-03-07 Eth Zuerich moduladores ror gama
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
ES2672732T3 (es) 2012-02-07 2018-06-15 Eolas Therapeutics Inc. Prolinas/piperidinas sustituidas como antagonistas del receptor de orexina
US9249160B2 (en) 2012-07-03 2016-02-02 Heptares Therapeutics Limited Orexin receptor antagonists
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2781217A1 (de) 2013-03-18 2014-09-24 ETH Zurich ROR-Gammamodulatoren
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP6663909B2 (ja) 2014-08-13 2020-03-13 エオラス セラピューティクス, インコーポレイテッド オレキシンレセプターモジュレーターとしてのジフルオロピロリジン
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
GB201601301D0 (en) * 2016-01-25 2016-03-09 Takeda Pharmaceutical Novel compounds
MX2018009656A (es) 2016-02-12 2019-02-20 Astrazeneca Ab Piperidinas halo-sustituidas como moduladores de los receptores de orexinas.
US20190151304A1 (en) 2016-05-10 2019-05-23 Inserm (Institut National De La Santé Et De La Rechercjae Médicale Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory
AR109950A1 (es) 2016-10-14 2019-02-06 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
GB201718256D0 (en) * 2017-11-03 2017-12-20 Heptares Therapeutics Ltd Ox1 antagonists
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
JP2025530213A (ja) 2022-09-09 2025-09-11 ミリックス ファーマ リミテッド Nmt阻害剤を含む抗体薬物コンジュゲート及びその使用
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
CN119977904A (zh) * 2025-02-18 2025-05-13 合肥工业大学 一种苯并氧(碳/硫)氮杂䓬类化合物及其在医学上的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236838A (en) * 1964-06-09 1966-02-22 Hoffmann La Roche Certain 1-substituted-benzodiazepin-2-one compounds
US3480714A (en) * 1966-02-07 1969-11-25 Ciba Geigy Corp N-substituted isoquinolines as antiprotozoal agents
CO5140073A1 (es) 1998-10-08 2002-03-22 Smithkline Beecham Plc Derivados de 2,3,4,5-tetrahidro-1h-3-benzapina

Also Published As

Publication number Publication date
CA2431982C (en) 2010-07-20
ES2296825T3 (es) 2008-05-01
CN1261430C (zh) 2006-06-28
JP4219166B2 (ja) 2009-02-04
IL155806A (en) 2008-03-20
EP1347967A1 (de) 2003-10-01
IL155806A0 (en) 2003-12-23
DE60132017T2 (de) 2008-12-04
KR100849569B1 (ko) 2008-07-31
JP2004516324A (ja) 2004-06-03
CA2431982A1 (en) 2002-07-04
NO20032905D0 (no) 2003-06-24
US7192950B2 (en) 2007-03-20
BR0116505A (pt) 2004-02-03
HUP0301665A2 (en) 2008-07-28
WO2002051232A2 (en) 2002-07-04
ZA200303697B (en) 2004-08-13
MXPA03004779A (es) 2003-09-25
EP1347967B1 (de) 2007-12-19
AU2002240855B2 (en) 2006-08-17
CN1481380A (zh) 2004-03-10
KR20030069199A (ko) 2003-08-25
HUP0301665A3 (en) 2008-12-29
NZ525613A (en) 2005-01-28
NO20032905L (no) 2003-06-24
WO2002051838A1 (en) 2002-07-04
US20040058912A1 (en) 2004-03-25
DE60132017D1 (de) 2008-01-31
NO326158B1 (no) 2008-10-13

Similar Documents

Publication Publication Date Title
ATE381560T1 (de) Neue benzazepine und ähnliche heterocyclische derivate,die als orexin rezeptor antagonisten geeignet sind
ATE300533T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate als urotensin ii rezeptor-antagonisten
PT1274687E (pt) Derivados de 1,2,3,4-tetra-hidroisoquinolina
MXPA05010137A (es) Derivados de tetrahidroisoquinolil acetamida para usarse como antagonistas del receptor de orexina.
ATE496884T1 (de) Sulphonylaminoessigsaeure derivate und deren verwendung als orexin rezeptor antagoniste
ATE312090T1 (de) 4-(piperidyl- und pyrrolidyl-alkyl-ureido)- chinoline als urotensin ii rezeptor antagonisten
MXPA03004780A (es) Nuevas sulfamidas.
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
ATE383345T1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
MY135916A (en) Use of certain affinity nmda antagonists as antidepressants
MXPA04001252A (es) Nuevos heterociclos benzo-fusionados como antagonistas de endotelina.
DE60116106D1 (de) Benzofuran derivate und ihre verwendung als antibakterielle wirkstoffe
MY140724A (en) Novel arylethene-sulfonamides
ATE386525T1 (de) 3-substituierte 6,7- dihydroxytetrahydroisochinolin-derivate zur verwendung als antibkaterielle mittel
MXPA02006250A (es) Derivados de butino diol.
WO2000037465A3 (en) Novel derivatives of swainsonine, processes for their preparation, and their use as therapeutic agents

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1347967

Country of ref document: EP